CO2017001601A2 - Derivados de 1-acetil-4-((pirazin-2-il) amino)-1,2,3,4-tetrahydroquinolina-6 carboxamida como inhibidores de bromodominio - Google Patents

Derivados de 1-acetil-4-((pirazin-2-il) amino)-1,2,3,4-tetrahydroquinolina-6 carboxamida como inhibidores de bromodominio

Info

Publication number
CO2017001601A2
CO2017001601A2 CONC2017/0001601A CO2017001601A CO2017001601A2 CO 2017001601 A2 CO2017001601 A2 CO 2017001601A2 CO 2017001601 A CO2017001601 A CO 2017001601A CO 2017001601 A2 CO2017001601 A2 CO 2017001601A2
Authority
CO
Colombia
Prior art keywords
tetrahydroquinoline
pyrazin
acetyl
amino
carboxamide derivatives
Prior art date
Application number
CONC2017/0001601A
Other languages
English (en)
Inventor
Stephen John Atkinson
David Jonathan Hirst
Jonathan Thomas Seal
Christopher Roland Wellaway
Philip G Humphreys
Matthew J Lindon
Alexander G Preston
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of CO2017001601A2 publication Critical patent/CO2017001601A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a nuevos compuestos, a composiciones farmacéuticas que contienen tales compuestos y a su uso en terapia.
CONC2017/0001601A 2014-09-12 2017-02-17 Derivados de 1-acetil-4-((pirazin-2-il) amino)-1,2,3,4-tetrahydroquinolina-6 carboxamida como inhibidores de bromodominio CO2017001601A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462049449P 2014-09-12 2014-09-12
PCT/EP2015/070665 WO2016038120A1 (en) 2014-09-12 2015-09-09 Tetrahydroquinoline derivatives as bromodomain inhibitors

Publications (1)

Publication Number Publication Date
CO2017001601A2 true CO2017001601A2 (es) 2017-07-28

Family

ID=54065889

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0001601A CO2017001601A2 (es) 2014-09-12 2017-02-17 Derivados de 1-acetil-4-((pirazin-2-il) amino)-1,2,3,4-tetrahydroquinolina-6 carboxamida como inhibidores de bromodominio

Country Status (35)

Country Link
US (1) US10059699B2 (es)
EP (1) EP3191476B1 (es)
JP (1) JP6531167B2 (es)
KR (1) KR20170054421A (es)
CN (1) CN106687453B (es)
AR (1) AR101806A1 (es)
AU (1) AU2015314184B2 (es)
BR (1) BR112017004580A2 (es)
CA (1) CA2958159A1 (es)
CL (1) CL2017000587A1 (es)
CO (1) CO2017001601A2 (es)
CR (1) CR20170090A (es)
CY (1) CY1121369T1 (es)
DK (1) DK3191476T3 (es)
DO (1) DOP2017000058A (es)
EA (1) EA031679B9 (es)
ES (1) ES2705623T3 (es)
HR (1) HRP20182064T1 (es)
HU (1) HUE041694T2 (es)
IL (1) IL250397A0 (es)
LT (1) LT3191476T (es)
MA (1) MA40366A (es)
MX (1) MX2017003219A (es)
PE (1) PE20170675A1 (es)
PH (1) PH12017500348B1 (es)
PL (1) PL3191476T3 (es)
PT (1) PT3191476T (es)
RS (1) RS58135B1 (es)
SG (1) SG11201701043UA (es)
SI (1) SI3191476T1 (es)
TR (1) TR201820050T4 (es)
TW (1) TWI686389B (es)
UY (1) UY36292A (es)
WO (1) WO2016038120A1 (es)
ZA (1) ZA201700883B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20151727A1 (es) 2013-03-14 2015-12-17 Boehringer Ingelheim Int Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c
EP3191487B1 (en) 2014-09-12 2019-08-07 Boehringer Ingelheim International GmbH Spirocyclic inhibitors of cathepsin c
WO2018111805A1 (en) 2016-12-13 2018-06-21 St. Jude Children's Research Hospital Tetrahydroquinoline-based bromodomain inhibitors
AU2019372121A1 (en) 2018-10-30 2021-05-27 Nuvation Bio Inc. Heterocyclic compounds as BET inhibitors
KR102677015B1 (ko) 2019-07-02 2024-06-19 누베이션 바이오 인크. Bet 억제제로서의 헤테로시클릭 화합물
EP4095128A1 (en) 2021-05-25 2022-11-30 Centre national de la recherche scientifique Tetrahydroquinoline (thq) coumpounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2415764A4 (en) * 2009-03-31 2012-08-08 Kowa Co PROPHYLACTIC AND / OR THERAPEUTIC AGENT AGAINST ANEMIA WITH A TETRAHYDROCHINOLINE COMPOUND AS AN ACTIVE SUBSTANCE
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB201106743D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201106750D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201107325D0 (en) 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
NZ710765A (en) * 2013-03-14 2020-05-29 Glaxosmithkline Ip No 2 Ltd 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors

Also Published As

Publication number Publication date
CN106687453A8 (zh) 2017-06-30
JP6531167B2 (ja) 2019-06-12
PH12017500348A1 (en) 2017-07-17
PE20170675A1 (es) 2017-06-13
RS58135B1 (sr) 2019-02-28
TW201625587A (zh) 2016-07-16
CY1121369T1 (el) 2020-05-29
EP3191476A1 (en) 2017-07-19
TR201820050T4 (tr) 2019-01-21
CL2017000587A1 (es) 2017-10-06
AU2015314184B2 (en) 2018-09-13
PL3191476T3 (pl) 2019-04-30
CR20170090A (es) 2017-05-08
PT3191476T (pt) 2019-01-17
BR112017004580A2 (pt) 2018-01-23
EA031679B1 (ru) 2019-02-28
DOP2017000058A (es) 2017-06-15
MA40366A (fr) 2017-07-19
KR20170054421A (ko) 2017-05-17
SG11201701043UA (en) 2017-03-30
CN106687453B (zh) 2019-07-19
SI3191476T1 (sl) 2019-01-31
ZA201700883B (en) 2021-08-25
US10059699B2 (en) 2018-08-28
EA201790484A1 (ru) 2017-10-31
EP3191476B1 (en) 2018-10-24
ES2705623T3 (es) 2019-03-26
HRP20182064T1 (hr) 2019-02-08
LT3191476T (lt) 2019-01-10
WO2016038120A1 (en) 2016-03-17
HUE041694T2 (hu) 2019-05-28
EA031679B9 (ru) 2019-04-30
AR101806A1 (es) 2017-01-11
DK3191476T3 (en) 2019-01-14
JP2017526718A (ja) 2017-09-14
IL250397A0 (en) 2017-03-30
CA2958159A1 (en) 2016-03-17
CN106687453A (zh) 2017-05-17
MX2017003219A (es) 2017-06-19
PH12017500348B1 (en) 2017-07-17
AU2015314184A1 (en) 2017-03-09
TWI686389B (zh) 2020-03-01
UY36292A (es) 2016-04-29
US20170298047A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2016001889A1 (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1.
CO2017001601A2 (es) Derivados de 1-acetil-4-((pirazin-2-il) amino)-1,2,3,4-tetrahydroquinolina-6 carboxamida como inhibidores de bromodominio
MX2019001125A (es) Inhibidores de cinasa macrociclica.
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
EP3515420C0 (en) PHARMACEUTICAL COMPOSITIONS FOR USE IN BLEPHARITIS THERAPY
BR112017008659A2 (pt) ?métodos e compostos de agonista de gip?
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
BR112015023417A2 (pt) compostos heterocíclicos e seus usos
CL2015002897A1 (es) Inhibidores de bace1
MY191590A (en) 9h-pyrrolo-dipyridine derivatives
EA202090683A3 (ru) Способы и композиции для лечения рака
CL2014001047A1 (es) Compuestos heterociclicos derivados de pirazina; composicion y combinacion farmaceutica que los contienen y el uso en enfermedades respiratorias y alergicas.
EA202191513A1 (ru) Снижение вязкости фармацевтических составов
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
BR112017008481A2 (pt) composto antimicótico
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
BR112016028518A2 (pt) composições farmacêuticas que compreendem dgla e uso do mesmo
CL2020000056A1 (es) Nuevos derivados de xantina sustituidos.
BR112017008867A2 (pt) inibidores de proteína quinases